MCID: BLD039
MIFTS: 37

Bladder Adenocarcinoma

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Bladder Adenocarcinoma

MalaCards integrated aliases for Bladder Adenocarcinoma:

Name: Bladder Adenocarcinoma 12 15 17 72
Bladder Adenocarcinoma, Not Otherwise Specified 12
Adenocarcinoma of the Urinary Bladder 12
Adenocarcinoma of Bladder 12
Adenocarcinoma Bladder 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3711
NCIt 50 C39836 C4032
UMLS 72 C0279682

Summaries for Bladder Adenocarcinoma

Disease Ontology : 12 A bladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Bladder Adenocarcinoma, also known as bladder adenocarcinoma, not otherwise specified, is related to clear cell adenocarcinoma and villous adenoma, and has symptoms including dysuria An important gene associated with Bladder Adenocarcinoma is UCA1 (Urothelial Cancer Associated 1), and among its related pathways/superpathways are Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases and Pathways Affected in Adenoid Cystic Carcinoma. The drugs Bevacizumab and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include prostate, lung and colon, and related phenotype is neoplasm.

Related Diseases for Bladder Adenocarcinoma

Diseases related to Bladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)
# Related Disease Score Top Affiliating Genes
1 clear cell adenocarcinoma 30.2 KRT7 KRT20
2 villous adenoma 30.1 KRT20 CDX2
3 linitis plastica 29.8 KRT7 KRT20
4 tubular adenocarcinoma 29.6 KRT20 CDX2
5 mammary paget's disease 29.6 KRT7 KRT20
6 inverted papilloma 29.5 KRT7 KRT20
7 mucinous cystadenocarcinoma 29.4 KRT7 KRT20
8 carcinosarcoma 29.4 KRT7 HRAS CTNNB1
9 transitional cell carcinoma 29.1 KRT7 KRT20 HRAS
10 appendix adenocarcinoma 29.1 KRT7 KRT20 CDX2
11 mucinous adenocarcinoma 29.1 KRT7 KRT20 CDX2
12 cystadenocarcinoma 29.1 KRT7 HRAS FBXW7
13 rectum adenocarcinoma 28.7 KRT7 KRT20 CDX2
14 adenocarcinoma in situ 28.7 KRT7 KRT20 CDX2
15 signet ring cell adenocarcinoma 28.7 KRT7 KRT20 CDX2
16 endometrial cancer 28.6 UCA1 KRT7 HRAS CTNNB1
17 gastric cancer 28.6 UCA1 KRT20 CTNNB1 CDX2
18 cystitis cystica 28.4 KRT7 KRT20 CTNNB1 CDX2
19 glandular cystitis 28.4 UCA1 KRT7 KRT20 CDX2
20 colorectal adenocarcinoma 27.8 KRT7 KRT20 HRAS CTNNB1 CDX2
21 gastric adenocarcinoma 27.6 KRT7 KRT20 HRAS CTNNB1 CDX2
22 lung cancer susceptibility 3 27.6 KRT7 KRT20 HRAS CTNNB1 CDX2
23 pelvic lipomatosis 11.3
24 bladder clear cell adenocarcinoma 11.3
25 bladder signet ring cell adenocarcinoma 11.3
26 bladder colonic type adenocarcinoma 11.3
27 bladder urachal adenocarcinoma 11.3
28 bladder tubulo-cystic clear cell adenocarcinoma 11.3
29 bladder papillary clear cell adenocarcinoma 11.3
30 bladder hepatoid adenocarcinoma 11.3
31 adenocarcinoma 10.7
32 gallbladder adenoma 10.4 HRAS CTNNB1
33 goblet cell carcinoid 10.3 KRT20 CTNNB1
34 bladder cancer 10.3
35 skin squamous cell carcinoma 10.2 HRAS FBXW7
36 hepatoid adenocarcinoma 10.2
37 hydronephrosis 10.2
38 nephrogenic adenoma 10.2
39 serous cystadenocarcinoma 10.1 HRAS FBXW7
40 urachal adenocarcinoma 10.1
41 vaginal tubulovillous adenoma 10.1 KRT20 CDX2
42 vaginal adenoma 10.1 KRT20 CDX2
43 vaginal benign neoplasm 10.1 KRT20 CDX2
44 colorectal adenoma 10.1 HRAS CTNNB1
45 skin benign neoplasm 10.1 KRT20 HRAS
46 endometriosis 10.1
47 papillary craniopharyngioma 10.1 KRT7 CTNNB1
48 craniopharyngioma 10.1 KRT7 CTNNB1
49 uterine carcinosarcoma 10.1 HRAS FBXW7 CTNNB1
50 exstrophy of bladder 10.1

Graphical network of the top 20 diseases related to Bladder Adenocarcinoma:



Diseases related to Bladder Adenocarcinoma

Symptoms & Phenotypes for Bladder Adenocarcinoma

UMLS symptoms related to Bladder Adenocarcinoma:


dysuria

MGI Mouse Phenotypes related to Bladder Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 8.92 CDX2 CTNNB1 FBXW7 HRAS

Drugs & Therapeutics for Bladder Adenocarcinoma

Drugs for Bladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 2 216974-75-3
2
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
3
Ifosfamide Approved Phase 2 3778-73-2 3690
4
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
5
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
6
Gemcitabine Approved Phase 2 95058-81-4 60750
7
leucovorin Approved Phase 2 58-05-9 143 6006
8
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
9
nivolumab Approved Phase 2 946414-94-4
10
Ipilimumab Approved Phase 2 477202-00-9
11
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
12
Vinblastine Approved Phase 2 865-21-4 241903 13342
13
Daunorubicin Approved Phase 2 20830-81-3 30323
14
Durvalumab Approved, Investigational Phase 2 1428935-60-7
15
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
16
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
18 Piritrexim Investigational Phase 2 72732-56-0
19
Rubitecan Investigational Phase 2 91421-42-0
20
Camptothecin Experimental Phase 2 7689-03-4
21 Angiogenesis Inhibitors Phase 2
22 Angiogenesis Modulating Agents Phase 2
23 Alkylating Agents Phase 2
24 Albumin-Bound Paclitaxel Phase 2
25
Isophosphamide mustard Phase 2 0
26 Antineoplastic Agents, Alkylating Phase 2
27 topoisomerase I inhibitors Phase 2
28 Anti-Infective Agents Phase 2
29 Immunosuppressive Agents Phase 2
30 Antineoplastic Agents, Immunological Phase 2
31 Antiviral Agents Phase 2
32 Antimetabolites Phase 2
33 Antimetabolites, Antineoplastic Phase 2
34 Immunologic Factors Phase 2
35 Folic Acid Antagonists Phase 2
36 Folate Phase 2
37 Vitamin B9 Phase 2
38 Vitamin B Complex Phase 2
39 Antineoplastic Agents, Phytogenic Phase 2
40 Tubulin Modulators Phase 2
41 Antimitotic Agents Phase 2
42 Topoisomerase Inhibitors Phase 2
43 Antibodies Phase 2
44 Antibodies, Monoclonal Phase 2
45 Immunoglobulins Phase 2
46 Anti-Bacterial Agents Phase 2
47
Liposomal doxorubicin Phase 2 31703
48 Antibiotics, Antitubercular Phase 2
49 Nucleic Acid Synthesis Inhibitors Phase 2
50 Dermatologic Agents Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Bladder Cancer: Open Versus Laparoscopic or Robotic Cystectomy. A Study to Determine the Feasibility of Randomization to Open Versus Minimal Access Cystectomy in Patients With Bladder Cancer. Unknown status NCT01196403 Phase 2
2 A Multicenter Phase II Study of Gemcitabine, Capecitabine and Bevacizumab for Locally Advanced or Metastatic Adenocarcinoma of the Gall Bladder or Biliary Ducts. Completed NCT01007552 Phase 2 Gemcitabine, Capecitabine and Bevacizumab
3 PHASE II STUDY OF PIRITREXIM IN ADVANCED CARCINOMA OF THE UROTHELIUM Completed NCT00002914 Phase 2 piritrexim
4 Phase II Trial of Paclitaxel, Cisplatin and Ifosfamide in Patients With Advanced Urothelial Tumors Completed NCT00002684 Phase 2 cisplatin;ifosfamide;paclitaxel
5 Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Advanced/Metastatic Urothelial Tract Tumors Completed NCT00006026 Phase 2 rubitecan
6 A Phase 2 Study of Avelumab in Combination With Bladder-Directed Radiation in Cisplatin-Ineligible Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder Recruiting NCT03747419 Phase 2 Avelumab
7 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Recruiting NCT03866382 Phase 2 Cabozantinib;Cabozantinib S-malate
8 Phase 2 Open Label Study of Durvalumab With Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer Recruiting NCT03912818 Phase 2 Carboplatin;Cisplatin;Doxorubicin;Gemcitabine;Methotrexate;Vinblastine
9 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
10 Phase I Study of Intravesical Recombinant Fowlpox - GM-CSF (rF-GM-CSF) and/or Recombinant Fowlpox-TRICOM (rF-TRICOM) in Patients With Bladder Carcinoma Scheduled for Cystectomy Terminated NCT00072137 Phase 1

Search NIH Clinical Center for Bladder Adenocarcinoma

Genetic Tests for Bladder Adenocarcinoma

Anatomical Context for Bladder Adenocarcinoma

MalaCards organs/tissues related to Bladder Adenocarcinoma:

41
Prostate, Lung, Colon, Skin, Liver, Lymph Node, Breast

Publications for Bladder Adenocarcinoma

Articles related to Bladder Adenocarcinoma:

(show top 50) (show all 140)
# Title Authors PMID Year
1
Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder. 9 38
18789486 2009
2
Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. 9 38
18670358 2008
3
[Expression of CDX2 in urinary bladder and urethra lesions]. 9 38
15074058 2004
4
Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. 9 38
11684954 2001
5
Primary seminal vesicle carcinoma: an immunohistochemical analysis of four cases. 9 38
10658909 2000
6
Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. 9 38
9522212 1998
7
A report of orbital metastasis from a urinary bladder adenocarcinoma. 38
31332150 2019
8
Reviewing the Demographic, Prognostic, and Treatment Factors of Primary Adenocarcinoma of the Bladder: A SEER Population-based Study. 38
31395362 2019
9
Mimickers of urothelial neoplasia. 38
30380401 2019
10
Carcinogen-induced bladder cancer in the FVB mouse strain is associated with glandular differentiation and increased Cd274/Pdl-1 expression. 38
31317053 2019
11
Non-urothelial carcinomas of the bladder. 38
30565306 2019
12
Treating bladder adenocarcinoma. 38
30687599 2018
13
Incidental Gall Bladder Adenocarcinoma in Cholecystectomy Specimens; A Single Center Experience and Review of the Literature. 38
31049173 2018
14
microRNA‑145 modulates migration and invasion of bladder cancer cells by targeting N‑cadherin. 38
29693148 2018
15
Primary bladder adenocarcinoma: Case report with long-term follow-up. 38
29785373 2018
16
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. 38
27048257 2018
17
Squamous Cell and Adenosquamous Carcinoma of Gall Bladder: a Clinicopathological Study of 8 Cases Isolated in 94 Cancers. 38
29203990 2017
18
Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. 38
28548125 2017
19
Concordant clear cell "mesonephric" carcinoma of the bladder and lung adenocarcinoma with clear cell features - multiple primaries versus metastatic neoplasms: a case report. 38
28494807 2017
20
Bladder Adenocarcinoma: A Persisting Diagnostic Dilemma. 38
28511402 2017
21
Bladder Metastases from Lung Cancer: Clinical and Pathological Implications: A Systematic Review. 38
28056456 2017
22
Carcinoma of Gall bladder with distant metastasis to breast parenchyma. Report of a case and review of literature. 38
27381065 2016
23
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. 38
27427223 2016
24
Mucinous adenocarcinoma of the bladder: A case report and review of the literature. 38
27703678 2016
25
Cutaneous metastasis: An unusual presenting feature of urologic malignancies. 38
27453667 2016
26
Intestinal metaplasia of the bladder in 89 patients: a study with emphasis on long-term outcome. 38
27267922 2016
27
[Clinical research of second resection on early stage primary bladder adenocarcinoma and literature review]. 38
27266688 2016
28
Gallbladder adenocarcinoma and paraneoplastic parathyroid hormone mediated hypercalcemia. 38
27081650 2016
29
Differential diagnosis of bladder versus colorectal adenocarcinoma: keratin 7 and GATA3 positivity in nuclear ß-catenin-negative glandular tumours defines adenocarcinoma of the bladder. 38
26463756 2016
30
A novel treatment approach prolonging survival in an uncommon metastatic primary bladder adenocarcinoma. 38
26955660 2016
31
Urinary Bladder Adenocarcinoma Metastatic to the Abdominal Wall: Report of a Case with Cytohistologic Correlation. 38
27006847 2016
32
Anterior pelvic exenteration for exstrophic bladder adenocarcinoma: Case report and review. 38
27288750 2016
33
[A Case of Bladder Adenocarcinoma with Rectal Metastasis]. 38
26805326 2015
34
Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study. 38
25930983 2015
35
Gall bladder Adenocarcinoma in a Young Girl. 38
26139973 2015
36
Exfoliative erythroderma as a paraneoplastic presentation of adenocarcinoma of the gallbladder. 38
25830047 2015
37
Mucinous Bladder Adenocarcinoma: Case Report and Literature Review. 38
26421206 2015
38
Lymph node metastases in patients with urothelial carcinoma variants: influence of the specific variant on nodal histology. 38
25047418 2015
39
Serotonin and cancer: what is the link? 38
25601469 2015
40
Adenocarcinoma of the urinary bladder. 38
26309895 2015
41
En Bloc Robot-assisted Laparoscopic Partial Cystectomy, Urachal Resection, and Pelvic Lymphadenectomy for Urachal Adenocarcinoma. 38
26029004 2015
42
Complete response of primary bladder adenocarcinoma with the FOLFOX4 regimen. 38
24281125 2015
43
Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. 38
25029122 2014
44
Bladder metastasis from lung adenocarcinoma: a difficult differential diagnosis with primary bladder adenocarcinoma. 38
24716732 2014
45
Xanthogranulomatous cholecystitis: a rare cause of digestive hemorrhage. 38
24411821 2014
46
Hepatobiliary and pancreatic: coexisting cancers: Hepatic neuroendocrine carcinomas with gall bladder adenocarcinoma. 38
25040620 2014
47
The expression patterns of p53 and p16 and an analysis of a possible role of HPV in primary adenocarcinoma of the urinary bladder. 38
24752337 2014
48
EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder. 38
23887300 2014
49
GATA-3 immunohistochemistry in the differential diagnosis of adenocarcinoma of the urinary bladder. 38
24061521 2013
50
A metastatic cancer to skin in an otherwise asymptomatic young man: an unusual presentation. 38
24139375 2013

Variations for Bladder Adenocarcinoma

Expression for Bladder Adenocarcinoma

Search GEO for disease gene expression data for Bladder Adenocarcinoma.

Pathways for Bladder Adenocarcinoma

GO Terms for Bladder Adenocarcinoma

Biological processes related to Bladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vasculogenesis GO:0001570 9.16 FBXW7 CTNNB1
2 negative regulation of gene expression GO:0010629 9.13 HRAS FBXW7 CTNNB1
3 vasculature development GO:0001944 8.62 FBXW7 CTNNB1

Sources for Bladder Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....